AVEO Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AVEO)

$2.91 -0.09 (-3.00 %)
(As of 02/21/2018 06:12 AM ET)
Previous Close$3.00
Today's Range$2.88 - $3.04
52-Week Range$0.50 - $4.24
Volume1.37 million shs
Average Volume1.79 million shs
Market Capitalization$354.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).

Receive AVEO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960

Debt

Debt-to-Equity Ratio-0.32%
Current Ratio2.33%
Quick Ratio2.33%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.52 million
Price / Sales136.63
Cash FlowN/A
Price / CashN/A
Book Value($0.03) per share
Price / Book-97.00

Profitability

Trailing EPS($0.71)
Net Income$-26,880,000.00
Net Margins-972.31%
Return on EquityN/A
Return on Assets-80.17%

Miscellaneous

Employees20
Outstanding Shares118,320,000

AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) posted its quarterly earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.00. The biopharmaceutical company earned $2.53 million during the quarter. View AVEO Pharmaceuticals' Earnings History.

Where is AVEO Pharmaceuticals' stock going? Where will AVEO Pharmaceuticals' stock price be in 2018?

4 analysts have issued 12-month price objectives for AVEO Pharmaceuticals' shares. Their predictions range from $3.00 to $5.00. On average, they anticipate AVEO Pharmaceuticals' share price to reach $4.17 in the next year. View Analyst Ratings for AVEO Pharmaceuticals.

Who are some of AVEO Pharmaceuticals' key competitors?

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:

  • Michael P. Bailey, President, Chief Executive Officer, Director (Age 49)
  • Matthew Dallas, Chief Financial Officer (Age 41)
  • Nikhil Mehta Ph.D., Senior Vice President - Regulatory and Quality Assurance
  • Michael N. Needle M.D., Chief Medical Officer (Age 55)
  • Henri A. Termeer, Lead Out Side Director (Age 71)
  • Kenneth M. Bate, Independent Director (Age 66)
  • Anthony B. Evnin Ph.D., Independent Director (Age 76)
  • John H. Johnson, Independent Director (Age 58)
  • Robert C. Young M.D., Independent Director (Age 75)

Who owns AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (2.50%), Sphera Funds Management LTD. (1.10%), Prosight Management LP (0.89%), Geode Capital Management LLC (0.56%), EAM Investors LLC (0.53%) and Emory University (0.51%). View Institutional Ownership Trends for AVEO Pharmaceuticals.

Who sold AVEO Pharmaceuticals stock? Who is selling AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, EAM Investors LLC, Spark Investment Management LLC and Sphera Funds Management LTD.. View Insider Buying and Selling for AVEO Pharmaceuticals.

Who bought AVEO Pharmaceuticals stock? Who is buying AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Prosight Management LP, Emory University, Armistice Capital LLC, Goldman Sachs Group Inc., X Square Capital LLC, Two Sigma Advisers LP, Victory Capital Management Inc. and Virtus Fund Advisers LLC. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy AVEO Pharmaceuticals stock?

Shares of AVEO Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO Pharmaceuticals stock can currently be purchased for approximately $2.91.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $354.98 million and generates $2.52 million in revenue each year. The biopharmaceutical company earns $-26,880,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis. AVEO Pharmaceuticals employs 20 workers across the globe.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (AVEO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  209 (Vote Underperform)
Total Votes:  424
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AVEO Pharmaceuticals (NASDAQ:AVEO) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.17$4.17$4.17$3.25
Price Target Upside: 34.41% upside34.41% upside37.97% upside13.64% upside

AVEO Pharmaceuticals (NASDAQ:AVEO) Consensus Price Target History

Price Target History for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ:AVEO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018B. RileyReiterated RatingBuy$5.00HighView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuyN/AView Rating Details
8/28/2017Piper Jaffray CompaniesBoost Price TargetOverweight$3.80 -> $4.50HighView Rating Details
7/13/2017FBR & CoReiterated RatingOutperform$3.00HighView Rating Details
(Data available from 2/21/2016 forward)

Earnings

AVEO Pharmaceuticals (NASDAQ:AVEO) Earnings History and Estimates Chart

Earnings by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ AVEO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.05)($0.02)$6.50 million$4.61 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.10)($0.08)$4.00 million$0.35 millionViewN/AView Earnings Details
5/4/2017Q1 2017($0.12)($0.12)$2.53 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.09)($0.11)$0.13 millionViewN/AView Earnings Details
11/4/2016Q3 2016($0.12)($0.07)$0.99 millionViewN/AView Earnings Details
8/4/2016Q2 2016($0.14)($0.13)$0.19 millionViewN/AView Earnings Details
5/10/2016Q1($0.12)($0.13)$1.00 million$1.20 millionViewN/AView Earnings Details
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details
11/9/2015Q315($0.09)$0.14$15.16 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)($0.10)$0.13 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.21)$0.13 millionViewN/AView Earnings Details
3/6/2015Q314($0.28)($0.27)$0.12 millionViewListenView Earnings Details
11/5/2014Q3 2014($0.27)($0.28)$0.33 million$0.87 millionViewN/AView Earnings Details
8/11/2014Q214($0.38)($0.35)$0.35 million$1.85 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.33)($0.12)$0.38 million$15.29 millionViewN/AView Earnings Details
3/13/2014Q413($0.33)($0.32)$0.14 million$0.32 millionViewListenView Earnings Details
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.32 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details
4/28/2011Q1 2011($0.57)$2.28ViewN/AView Earnings Details
2/16/2011Q4 2010($0.64)($0.30)ViewN/AView Earnings Details
11/4/2010Q3 2010($0.62)($0.60)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.35)($0.50)ViewN/AView Earnings Details
4/29/2010Q1 2010($0.81)($2.27)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

AVEO Pharmaceuticals (NASDAQ:AVEO) Earnings Estimates

2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.06)($0.06)($0.06)
Q2 20181($0.06)($0.06)($0.06)
Q3 20181($0.06)($0.06)($0.06)
Q4 20181($0.06)($0.06)($0.06)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for AVEO Pharmaceuticals (NASDAQ:AVEO)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 54.23%
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals (NASDAQ AVEO) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/28/2017Equity Opportunities Iv GrowthMajor ShareholderBuy6,000,000$0.50$3,000,000.00View SEC Filing  
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.2034,121View SEC Filing  
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AVEO Pharmaceuticals (NASDAQ AVEO) News Headlines

Source:
DateHeadline
Zai Lab (ZLAB) vs. AVEO Pharmaceuticals (AVEO) Head-To-Head AnalysisZai Lab (ZLAB) vs. AVEO Pharmaceuticals (AVEO) Head-To-Head Analysis
www.americanbankingnews.com - February 12 at 11:36 AM
Ex-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud caseEx-Aveo Pharmaceuticals exec avoids max penalty in SEC fraud case
www.reuters.com - February 10 at 9:43 AM
AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Rating of "Hold" by BrokeragesAVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 8 at 1:32 AM
AVEO Announces Appointment of John H. Johnson to Board of DirectorsAVEO Announces Appointment of John H. Johnson to Board of Directors
finance.yahoo.com - February 2 at 9:19 AM
How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid?How Much is AVEO Pharmaceuticals Inc’s (NASDAQ:AVEO) CEO Getting Paid?
finance.yahoo.com - January 26 at 9:08 AM
Biotech Forum Daily Digest For January 21st - Seeking AlphaBiotech Forum Daily Digest For January 21st - Seeking Alpha
seekingalpha.com - January 24 at 8:06 AM
Blog Exposure - AVEO Pharma Presents Data from Phase-1b/2 Study of Tivozanib in Patients with Advanced HCCBlog Exposure - AVEO Pharma Presents Data from Phase-1b/2 Study of Tivozanib in Patients with Advanced HCC
finance.yahoo.com - January 23 at 5:26 PM
Ex-Aveo Pharmaceuticals exec fights SEC draconian penalty requestEx-Aveo Pharmaceuticals exec fights SEC 'draconian' penalty request
www.reuters.com - January 18 at 4:24 PM
AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Recommendation of "Hold" from BrokeragesAVEO Pharmaceuticals, Inc. (AVEO) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 14 at 1:32 AM
Heres Why AVEO Oncology Rose as Much as 13.7% Today - Motley FoolHere's Why AVEO Oncology Rose as Much as 13.7% Today - Motley Fool
www.fool.com - January 13 at 3:39 PM
Here's Why AVEO Oncology Rose as Much as 13.7% TodayHere's Why AVEO Oncology Rose as Much as 13.7% Today
finance.yahoo.com - January 13 at 11:05 AM
AVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare ConferenceAVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 11:11 AM
SEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals execSEC seeks penalty, 5-year ban for ex-Aveo Pharmaceuticals exec
www.reuters.com - January 2 at 9:13 PM
AVEO Oncology Announces Refinanced Debt FacilityAVEO Oncology Announces Refinanced Debt Facility
finance.yahoo.com - January 2 at 9:13 PM
Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Rounds Off Refinancing of Debt Facility with HerculesCompany Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Rounds Off Refinancing of Debt Facility with Hercules
finance.yahoo.com - January 2 at 9:13 PM
AVEO Pharmaceuticals (AVEO) Coverage Initiated at B. RileyAVEO Pharmaceuticals (AVEO) Coverage Initiated at B. Riley
www.americanbankingnews.com - December 31 at 3:38 PM
Aveo settles investor lawsuit over cancer drug for $15 mln, warrants - ReutersAveo settles investor lawsuit over cancer drug for $15 mln, warrants - Reuters
www.reuters.com - December 27 at 8:26 PM
BRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action LawsuitBRIEF-Aveo Pharma Entered Into Binding MoU With Class Representatives Regarding Settlement Of A 2013 Class Action Lawsuit
www.businessinsider.com - December 26 at 8:48 PM
AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Recommendation of "Buy" by BrokeragesAVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - December 20 at 1:28 AM
Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock OptionsImplied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
finance.yahoo.com - December 19 at 11:21 AM
AVEO Pharmaceuticals, Inc. (AVEO) Short Interest UpdateAVEO Pharmaceuticals, Inc. (AVEO) Short Interest Update
www.americanbankingnews.com - December 15 at 3:08 AM
AVEO Pharmaceuticals (AVEO) & Its Competitors Critical SurveyAVEO Pharmaceuticals (AVEO) & Its Competitors Critical Survey
www.americanbankingnews.com - December 8 at 11:22 AM
BRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab ProgramsBRIEF-Aveo Oncology Announces Clinical Updates To Tivozanib And Ficlatuzumab Programs
www.reuters.com - December 7 at 11:50 AM
AVEO Oncology Announces Clinical Updates to Tivozanib and Ficlatuzumab ProgramsAVEO Oncology Announces Clinical Updates to Tivozanib and Ficlatuzumab Programs
finance.yahoo.com - December 7 at 11:50 AM
AVEO Pharmaceuticals, Inc. (AVEO) Continues to Build Strong Momentum in Its Oncology ProgramsAVEO Pharmaceuticals, Inc. (AVEO) Continues to Build Strong Momentum in Its Oncology Programs
finance.yahoo.com - December 7 at 11:50 AM
AVEO Pharmaceuticals (AVEO) Downgraded by Zacks Investment Research to "Sell"AVEO Pharmaceuticals (AVEO) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - December 6 at 5:40 PM
BRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 MlnBRIEF-Aveo Pharmaceuticals Files For Mixed Shelf Of Upto $200 Mln
www.reuters.com - December 1 at 6:30 PM
AVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Buy" from AnalystsAVEO Pharmaceuticals, Inc. (AVEO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - November 25 at 1:48 AM
Ex-Aveo Pharmaceuticals CEO settles SEC fraud claimsEx-Aveo Pharmaceuticals CEO settles SEC fraud claims
www.reuters.com - November 20 at 10:32 PM
AVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality AssuranceAVEO Announces Appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance
finance.yahoo.com - November 20 at 5:32 PM
AVEO Pharmaceuticals, Inc. (AVEO) Names New Senior Vice President of Regulatory and Quality AssuranceAVEO Pharmaceuticals, Inc. (AVEO) Names New Senior Vice President of Regulatory and Quality Assurance
finance.yahoo.com - November 20 at 5:32 PM
 Initiates Coverage on AVEO Pharmaceuticals, Inc. (AVEO) Initiates Coverage on AVEO Pharmaceuticals, Inc. (AVEO)
www.americanbankingnews.com - November 19 at 4:20 PM
Cancer Space Update: Label Expansion for Three Major DrugsCancer Space Update: Label Expansion for Three Major Drugs
finance.yahoo.com - November 17 at 3:56 PM
What’s Installed For AVEO Pharmaceuticals Inc (AVEO)?What’s Installed For AVEO Pharmaceuticals Inc (AVEO)?
finance.yahoo.com - November 17 at 3:56 PM
EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)
finance.yahoo.com - November 16 at 11:39 AM
Brokers Offer Predictions for AVEO Pharmaceuticals, Inc.s FY2017 Earnings (AVEO)Brokers Offer Predictions for AVEO Pharmaceuticals, Inc.'s FY2017 Earnings (AVEO)
www.americanbankingnews.com - November 15 at 7:32 AM
AVEO Pharmaceuticals (AVEO) vs. Its Competitors Head-To-Head SurveyAVEO Pharmaceuticals (AVEO) vs. Its Competitors Head-To-Head Survey
www.americanbankingnews.com - November 12 at 3:10 AM
FY2017 Earnings Estimate for AVEO Pharmaceuticals, Inc. Issued By Seaport Global Securities (AVEO)FY2017 Earnings Estimate for AVEO Pharmaceuticals, Inc. Issued By Seaport Global Securities (AVEO)
www.americanbankingnews.com - November 10 at 8:34 AM
Pro-Trader Daily: Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and NivolumabPro-Trader Daily: Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab
www.finanznachrichten.de - November 9 at 4:34 AM
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda - NasdaqAVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda - Nasdaq
www.nasdaq.com - November 8 at 6:32 PM
Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and NivolumabCorporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab
finance.yahoo.com - November 8 at 6:32 PM
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on FotivdaAVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
finance.yahoo.com - November 8 at 6:32 PM
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October - Motley FoolWhy AVEO Pharmaceuticals, Inc. Tanked 18.6% in October - Motley Fool
www.fool.com - November 8 at 4:22 AM
Your Daily Pharma Scoop: Anxious Time For Dynavax Longs, VBL Therapeutics Gets A Boost, Roche Gets 2 FDA ApprovalsYour Daily Pharma Scoop: Anxious Time For Dynavax Longs, VBL Therapeutics Gets A Boost, Roche Gets 2 FDA Approvals
seekingalpha.com - November 7 at 6:17 PM
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in OctoberWhy AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
finance.yahoo.com - November 7 at 6:17 PM
AVEO Reports Third Quarter 2017 Financial Results and Provides Business UpdateAVEO Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 7 at 6:17 PM
AVEO reports 3Q lossAVEO reports 3Q loss
finance.yahoo.com - November 7 at 6:17 PM
Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Provides 3Q:17 UpdateCompany Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Provides 3Q:17 Update
finance.yahoo.com - November 7 at 6:17 PM
31 Stocks Moving In Mondays Mid-Day Session31 Stocks Moving In Monday's Mid-Day Session
www.benzinga.com - November 6 at 5:11 PM
AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell CarcinomaAVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma
finance.yahoo.com - November 6 at 5:11 PM

SEC Filings

AVEO Pharmaceuticals (NASDAQ:AVEO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AVEO Pharmaceuticals (NASDAQ:AVEO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AVEO Pharmaceuticals (NASDAQ AVEO) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.